Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product...( - Significant Efforts to Expand M...)

- Significant Efforts to Expand Market and Prepare for Zingo Launch

Underway - - Nancy Donahue Promoted To Senior Vice President, Marketing and Sales, and

James Carr Promoted To Vice President, Marketing -

- Additional Manufacturing Capacity in China - - Details to be Presented at Investor Briefing Today at 12 p.m. Eastern

Time -

SOUTH SAN FRANCISCO, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced key elements of the company's commercialization and launch plans for Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, to reduce pain associated with peripheral venous access procedures in children three to 18 years of age. In addition, at its noon briefing in New York City today, the company will review its ongoing efforts and plans to raise market awareness, gain hospital formulary acceptance and routine use, and build and expand manufacturing capacity, including:

-- creation of an Anesiva sales force of 15 reps and 2 district managers;

-- an agreement with Sagent Pharmaceuticals to co-promote Zingo focusing

on pharmacy and group purchase contracts;

-- the qualification of two automated manufacturing lines that will

produce commercial quantities of product;

-- availability of Zingo in commercial quantities in the second quarter

of 2008;

-- the promotions of Nancy Donahue and James Carr who will spearhead

Zingo sales and marketing efforts; and

-- a joint venture with Wanbang Pharmaceuticals, a company of Fosun

Pharmaceuticals of China to expand produ
'/>"/>